Creating the cannabinoid industry with Kevin Chen Episode 182

IN THIS EPISODE:  Kevin's main project is Hyasynth Bio. A startup focused on opening up the potential of cannabis-derived medicine, by replacing plant growth with engineered microorganisms. Kevin chats with Greg and Dave about his company, and explains the process of producing cannabinoids with yeast instead of growing plants, a manufacturing process which has been around sine the 1970's. Kevin shares his experiences as an entrepreneur in this sector and how Hyasynth differentiates itself from other cannabis business in the industry. BIO: Kevin Chen is the CEO and cofounder of Hyasynth, a company that is focused on producing cannabinoids, the active compounds in Cannabis, by using engineered yeast instead of growing plants. With a background in biochemistry, he has switched into a business role at Hyasynth when he started the company in 2014. He is passionate about all kinds of technology development, startups and also community development as a volunteer and director of his local makerspace.  Learn more about your ad choices. Visit megaphone.fm/adchoices